Bioequivalence Study of Linagliptin/Metformin Formulations in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of linagliptin/metformin in healthy volunteers. Bioequivalence studies are crucial in determining whether different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, ensuring therapeutic equivalence. This is clinically relevant as it ensures that patients receive the same therapeutic benefits and safety profile from different formulations of the same medication. No secondary objectives are provided for this study.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized as adults, although specific age details are not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for certain participants. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The absence of detailed inclusion or exclusion criteria suggests that the trial may have broad eligibility requirements, but this cannot be confirmed without further data.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of linagliptin/metformin in **healthy volunteers**. This study is a Phase 2 trial, which is expected to commence recruitment on September 18, 2024, and conclude by December 2, 2024. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive either the test formulation or the reference formulation, with neither the participants nor the investigators aware of the group assignments, thus maintaining the double-blind nature of the study.

The sequence of study visits begins with an inclusion visit, where potential participants undergo a screening process to determine eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend a series of follow-up visits. These visits are scheduled to monitor the participants' health status, adherence to the study protocol, and to collect necessary data for the assessment of bioequivalence. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted, and any remaining study-related procedures are completed.

The expected length of participant involvement in the trial is determined by the study's duration, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to ensure the safety and well-being of participants while achieving the study's objectives.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment protocols accurately.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. Information such as the parameters or endpoints used to evaluate efficacy, the methods and schedule for measuring, collecting, and analyzing these efficacy parameters, and any tools or instruments involved in efficacy assessments are not included. The trial is identified as a Phase 2 study, with an estimated recruitment start date of September 18, 2024, and an estimated end date of December 2, 2024. Further details on efficacy assessment are not available in the provided data.